Privium Fund Management B.V. Has $1.09 Million Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

Privium Fund Management B.V. lifted its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 80.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,000 shares of the company’s stock after purchasing an additional 39,166 shares during the period. Privium Fund Management B.V. owned 0.06% of Wave Life Sciences worth $1,089,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Wave Life Sciences by 209.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock valued at $6,926,000 after acquiring an additional 571,345 shares during the period. FMR LLC lifted its position in shares of Wave Life Sciences by 174.5% during the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after acquiring an additional 979,110 shares during the period. Maven Securities LTD acquired a new stake in shares of Wave Life Sciences during the 3rd quarter worth $6,970,000. Barclays PLC increased its position in shares of Wave Life Sciences by 171.1% in the third quarter. Barclays PLC now owns 159,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 100,498 shares during the period. Finally, Cinctive Capital Management LP raised its stake in Wave Life Sciences by 255.7% in the third quarter. Cinctive Capital Management LP now owns 356,308 shares of the company’s stock valued at $2,922,000 after purchasing an additional 256,146 shares in the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

WVE has been the topic of a number of analyst reports. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a research report on Wednesday, March 5th. Mizuho boosted their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Finally, Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price on the stock. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Wave Life Sciences presently has an average rating of “Moderate Buy” and an average target price of $22.60.

Wave Life Sciences Stock Down 3.7 %

Shares of WVE stock opened at $9.79 on Wednesday. Wave Life Sciences Ltd. has a twelve month low of $4.25 and a twelve month high of $16.74. The stock’s fifty day simple moving average is $11.06 and its 200 day simple moving average is $11.50. The firm has a market capitalization of $1.50 billion, a P/E ratio of -8.82 and a beta of -1.04.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.34. The company had revenue of $83.75 million for the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. As a group, equities research analysts expect that Wave Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 29.10% of the company’s stock.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.